ArticleTranslational cancer research2025
Development and validation of a pathomics model to predict SOX11 expression and prognosis in hepatocellular carcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: SOX11 is overexpressed in hepatocellular carcinoma (HCC), in which it promotes tumorigenesis and is associated with poor prognosis. This study aims to assess the prognostic value of SOX11 expression in HCC patients and to develop a predictive pathomics model based on this expression. Methods: We analyzed data from 335 HCC patients in The Cancer Genome Atlas (TCGA) database, including pathological images and gene expression profiles. Patients were stratified into high and low SOX11 expression groups based on RNA sequencing data for prognostic and survival analysis. A pathomics model was constructed using the light gradient boosting machine (LightGBM) algorithm. Its predictive performance was evaluated in terms of discrimination, calibration, clinical utility, and interpretability. Potential pathological mechanisms were investigated through differential gene expression, enrichment analysis, immune cell infiltration profiling, and gene mutation analysis. Results: SOX11 expression was significantly elevated in tumor tissues compared to normal tissues. High SOX11 expression was significantly associated with reduced overall survival (OS) in the HCC population, and this association remained significant after adjusting for multiple clinical covariates. Nine pathomics features were selected to construct a pathomics signature (PS) for predicting SOX11 expression. The PS demonstrated strong discriminative ability, with area under the curve (AUC) of 0.928 [95% confidence interval (CI): 0.895-0.959] in the training cohort, the mean AUC of the model after 5-fold cross-validation was 0.869 (95% CI: 0.824-0.895), and 0.830 (95% CI: 0.699-0.879) in the validation cohort. It also showed good calibration across all cohorts, and decision curve analysis (DCA) confirmed its clinical utility. Kaplan-Meier analysis indicated that high PS expression was associated with poorer OS. Conclusions: SOX11 expression may influence the prognosis of HCC patients. The PS can accurately and robustly predict both SOX11 expression and patient prognosis, making it a potentially valuable tool for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.